PROM1 and neoplasm: We observed that M-Gef-CD133 reduced the number of tumor spheres and the percentage of CD133+ lung CSCs more effectively than M-Gef and gefitinib, suggesting that M-Gef-CD133 preferably eliminates CD133+ lung CSCs.